Publications in collaboration with researchers from Beckman Research Institute (19)

2024

  1. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

2023

  1. A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer

    Molecular Cancer

  2. Combining Asian and European genome-wide association studies of colorectal cancer improves risk prediction across racial and ethnic populations

    Nature Communications, Vol. 14, Núm. 1

  3. Genetic Variants as Predictors of the Success of Colorectal Cancer Treatments

    Cancers, Vol. 15, Núm. 19

  4. Genome-wide methylation profiling identifies a novel gene signature for patients with synchronous colorectal cancer

    British Journal of Cancer, Vol. 128, Núm. 1, pp. 112-120

  5. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

    Blood Advances, Vol. 7, Núm. 17, pp. 4926-4935

2022

  1. A Liquid Biopsy Signature for the Detection of Patients With Early-Onset Colorectal Cancer

    Gastroenterology, Vol. 163, Núm. 5, pp. 1242-1251.e2

  2. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

    Leukemia and Lymphoma, Vol. 63, Núm. 4, pp. 821-833

2021

  1. A Liquid Biopsy Assay for Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer

    Gastroenterology, Vol. 161, Núm. 1, pp. 151-162.e1

  2. Genetic architectures of proximal and distal colorectal cancer are partly distinct

    Gut, Vol. 70, Núm. 7, pp. 1325-1334

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: An analysis from the Ovarian Cancer Cohort Consortium (OC3)

    Cancer Research, Vol. 80, Núm. 5, pp. 1210-1218

2019

  1. Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1)

    Nature Communications

2018

  1. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

    Nature Communications, Vol. 9, Núm. 1

  2. Germline variation at 8q24 and prostate cancer risk in men of European ancestry

    Nature Communications, Vol. 9, Núm. 1

2016

  1. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer

    Journal of Thoracic Oncology, Vol. 11, Núm. 1, pp. 39-51

2015

  1. Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 6, pp. 971-983

2014

  1. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33

    Human Molecular Genetics, Vol. 23, Núm. 24, pp. 6616-6633

2012

  1. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11

    Human Molecular Genetics, Vol. 21, Núm. 24, pp. 5373-5384